Adamis Pharmaceuticals has reported that its Phase II/III clinical trial of Tempol (MBM-02) in increased-risk patients with early Covid-19 failed to meet the primary endpoint.

The double-blind, randomised, adaptive, placebo-controlled trial analysed the impact of Tempol in Covid-19 patients.

It enrolled nearly 248 subjects aged 18 years and above. These patients received either a daily 800mg dose of Tempol or a placebo twice a day for up to 21 days. 

According to the third interim assessment data from the trial, Tempol did not show statistical significance on the primary endpoint of sustained clinical resolution of disease symptoms at day 14 compared to a placebo. 

Due to a lack of efficacy, the independent Data Safety Monitoring Board (DSMB) advised halting the trial early. 

The board also noted no safety concerns in trial subjects treated with Tempol. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based on the DSMB recommendation, the company stopped the study and will assess the unblinded trial results to decide on the further development of Tempol.

Adamis Pharmaceuticals chief medical officer Ron Moss said: “This trial did not meet its primary endpoint, but we are exploring the possibility that vaccinations and the less virulent variants [Omicron] during the trial period may have obscured an effect of Tempol. 

“This speculation is based on the lower-than-expected observed hospitalisation rate in this trial [less than 1%], compared to other Covid-19 treatment trials. 

“We will continue to analyse the data to determine if we believe Tempol can be utilised in other Covid patient populations, including those with more severe illness or immunocompromised.”

In June this year, the company reported that the DSMB overseeing the Phase II/III trial of Tempol for Covid-19 recommended the continuation of the study as planned.